Our management team has a long track record of working successfully in developing pharmaceutical drugs.
Michael Mehler, Ph.D.
Dr. Michael Mehler brings to leon-nanodrugs over 25 years of experience holding significant leadership roles in the international pharma and biotechnology industries. In his previous tenure he was the CEO of SpePharm AG, Lucerne, a pan-European specialty pharma company focused on high-value specialty hospital products. Prior to that he led Riemser Arzneimittel AG, today Riemser Pharma GmbH, Greifswald, as CEO from 2009 to 2014 and guided the company through the sale to AXA Private Equity, today Ardian, in 2012. From 2003 to 2009 he served Actelion Pharmaceuticals, (Allschwil) in several senior executive roles, Michael started his long-time international career at Merck/MSD and Novartis.
Wolfgang Beier, Ph.D.
Dr. Wolfgang Beier is the Chief Scientific Officer and one of the main co-founder of leon-nanodrugs. He has 35 years of international R&D experience in the pharmaceutical industry and in the CRO-business. He held senior executive management R&D positions in various pharma companies (Byk Gulden, Akzo etc.) and he has deep experience with FDA/EMA drug approvals. He focused on drug development in oncology and was a founder and CEO of PFK Pharma Research (CRO), CEO of PFK-ILEX Oncology and co-founder and CEO of Onoclogy World, Munich.
Michael Grau is the Chief Financial Officer of leon-nanodrugs. Michael has an impressive track record of 25 years’ experience in corporate finance, controlling, finance and general management in diverse industries, since 2001 with a focus on life sciences. He was responsible for multiple capital market transactions, several international merger and acquisition agreements and for the financial components of several large scale international corporate alliances. Michael has recently served as CFO at Proteros Biostructures GmbH, Ingenium, Munich and Correvio LLC a Geneva based Hospital Specialty Pharma Company